Properdin, Human, mAb 2.9
The monoclonal antibody 2.9 reacts with human properdin (factor P), which is a single-chain plasma
glycoprotein with an apparent molecular mass of 52-55 kDa, The protein domain structure of
properdin consists of six thrombospondin repeat sequences between short N- and C-terminal
domains. In blood, properdin exists as a mixture of head-to-tail dimers, trimers and tetramers. The
protein is expressed by a variety of leukocytes, including monocytes, T lymphocytes and neutrophils,
but also by endothelial cells in which properdin synthesis is induced by certain stress factors.
Properdin participates in the alternative pathway of complement activation together with C3 and
factors B, D, I and H by prolonging the half-life of the labile C3bBb, which is deposited on immune
complexes or foreign surfaces. This permits amplification of C3bBb formation in competition with
catabolism of C3b by factor I, which uses factor H as a cofactor. The local amplification process leads
to the creation of the alternative pathway C5 convertase, C3bBb3b, and initiates the terminal pathway
of complement activation. As a consequence, properdin is consumed by binding to C3bBb, which
shows an order of preference of tetramers over trimers over dimers, which corresponds to the
functional activity of the oligomeric forms. Deficiency or malfunction of the molecule may lead to
severe impairment of alternative pathway activation, depending on the precise nature of the defect.
Three types of deficiencies have been described so far: type 1 (or I) is characterized by serum with
very low or absent properdin activity in hemolytic assays and <0.1 μg/ml immunoreactive protein; type 2 (or II) is characterized by low but detectable levels of immunoreactive protein (>2 μg/ml) and
impairment of some, but not all functional test, and type 3 (or III) has normal levels of immunoreactive
but dysfunctional protein (5-25 μg/mL). Lower properdin levels were found in 70% of diabetic patients
when compared to nondiabetic controls and is suggested by the authors that patients with low
expression of properdin take preventive measures and early treatments against infection. The
monoclonal antibody 2.9 is suitable for functional studies as well as use in immunoassays.
Calculate your ELISA data easily
With the ELISA calculator you can easily calculate ELISA data. Assayfit Pro helps to perform curve fitting. The calculator generates advanced reports, fit graph, fit parameters and goodness of fit are shown.
Latest Hycult Biotech news
- New Human Complement Pathway AssaysWe are very proud of our newly developed human classical and alternative complement pathway assays. They are produced in response to a growing demand for quantitative investigation of complement inhibitors or regulators at lower sample dilutions. This development aims to address the issue of false negative results, enabling more accurate and reliable analysis of complement… Read more: New Human Complement Pathway Assays
- Navigating the pitfalls in complement analysisOur colleague Erik Toonen shared his experience on how to analyze complement at the Complement-based Drug Development Summit in Boston in September 11-13th, 2023. He showed valuable insights on analyzing complements. For accurate complement analysis, it is important that not only the correct technique is used but also that pre-analytical sample handling is performed in… Read more: Navigating the pitfalls in complement analysis
- NEW Human C3d ELISAWe are happy to introduce our new ELISA (cat.# HK3017) designed to detect human C3d. What sets this assay apart is its utilization of a distinctive neo-epitope capture antibody that selectively targets a specific C3d region of the alpha chain, which is not available in other C3 variants. This way it specifically distinguishes C3d from native C3… Read more: NEW Human C3d ELISA